Enhancement of TPA-induced growth inhibition and apoptosis in myeloid leukemia cells by BAY 11-7082, an NF-κB inhibitor

International Journal of Oncology

Volumn 27, Issue 4, 2005, Pages 941-948

  Hansson, Annette ^a   Marín, Yarí E ^a   Suh, Junghan ^b   Rabson, Arnold B ^b,c   Chen, Suzie ^a   Huberman, Eliezer ^d   Chang, Richard L ^a   Conney, Allan H ^a,c   Zheng, Xi ^a  

^a RUTGERS UNIVERSITY   (United States)

^b RUTGERS UNIVERSITY   (United States)

^c RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^d ARGONNE NATIONAL LABORATORY   (United States)

Author keywords

Apoptosis; Myeloid leukemia; NF B inhibitor

Indexed keywords

3 (4 METHYLPHENYLSULFONYL) 2 PROPENENITRILE; 3-(4-METHYLPHENYLSULFONYL)-2-PROPENENITRILE; DNA; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NF KAPPAB INHIBITOR ALPHA; NF-KAPPAB INHIBITOR ALPHA; NITRILE; PHORBOL 13 ACETATE 12 MYRISTATE; PROPIDIUM IODIDE; PROTEIN KINASE C; PROTEIN KINASE C BETA; SULFONE;

ACTIVE TRANSPORT; APOPTOSIS; ARTICLE; CELL ADHESION; CELL DIFFERENTIATION; CELL NUCLEUS; CELL PROLIFERATION; CELL STRAIN HL 60; CELL SURVIVAL; CHEMISTRY; DNA DAMAGE; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; GENE EXPRESSION REGULATION; HUMAN; IMMUNOPHENOTYPING; METABOLISM; MYELOID LEUKEMIA; PHOSPHORYLATION; TIME; TUMOR CELL LINE;

ACTIVE TRANSPORT, CELL NUCLEUS; APOPTOSIS; CELL ADHESION; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL NUCLEUS; CELL PROLIFERATION; CELL SURVIVAL; DNA; DNA DAMAGE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HL-60 CELLS; HUMANS; I-KAPPA B PROTEINS; IMMUNOPHENOTYPING; LEUKEMIA, MYELOID; NF-KAPPA B; NITRILES; PHOSPHORYLATION; PROPIDIUM; PROTEIN KINASE C; SULFONES; TETRADECANOYLPHORBOL ACETATE; TIME FACTORS;

EID: 33644820912     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.27.4.941     Document Type: Article

References (42)

1. Smith M, Barnett M, Bassan R, Gatta G, Tondini C and Kern W: Adult acute myeloid leukaemia. Crit Rev Oncol Hematol 50: 197-222, 2004.
2. Ferrara F: Unanswered questions in acute myeloid leukaemia. Lancet Oncol 5: 443-450, 2004.
3. Debatin KM: Apoptosis pathways in cancer and cancer therapy. Cancer Immunol Immunother 53: 153-159, 2004.
4. Rovera G, O'Brien TG and Diamond L: Induction of differentiation in human promyelocytic leukemia cells by tumor promoters. Science 204: 868-870, 1979.
5. Lotem J and Sachs L: Regulation of normal differentiation in mouse and human myeloid leukemic cells by phorbol esters and the mechanism of tumor promotion. Proc Natl Acad Sci USA 76:5158-5162, 1979.
6. Huberman E and Callaham MF: Induction of terminal differentiation in human promyelocytic leukemia cells by tumorpromoting agents. Proc Natl Acad Sci USA 76: 1293-1297, 1979.
7. Han ZT, Zhu XX, Yang RY, Sun JZ, Tian GF, Liu XJ, Cao GS, Newmark HL, Conney AH and Chang RL: Effect of intravenous infusions of 12-O- tetradecanoylphorbol-13-acetate (TPA) in patients with myelocytic leukemia: preliminary studies on therapeutic efficacy and toxicity. Proc Natl Acad Sci USA 95: 5357-5361, 1998.
8. Strair RK, Schaar D, Goodell L, Aisner J, Chin KV, Eid J, Senzon R, Cui XX, Han ZT, Knox B, Rabson AB, Chang R and Conney A: Administration of a phorbol ester to patients with hematological malignancies: preliminary results from a phase I clinical trial of 12-O-tetradecanoylphorbol-13-acetate. Clin Cancer Res 8: 2512-2518, 2002.
9. 3, and sodium butyrate on differentiation in HL-60 cells. Oncol Res 12: 419-427, 2001.
10. Takada Y, Hachiya M, Osawa Y, Hasegawa Y, Ando K, Kobayashi Y and Akashi M: 12-O-tetradecanoylphorbol-13- acetate-induced apoptosis is mediated by tumor necrosis factor alpha in human monocytic U937 cells. J Biol Chem 274: 28286-28292, 1999.
11. Laouar A, Glesne D and Huberman E: Protein kinase C-beta, fibronectin, alpha(5)beta(1)-integrin, and tumor necrosis factoralpha are required for phorbol diester-induced apoptosis in human myeloid leukemia cells. Mol Carcinog 32: 195-205, 2001.
12. Rahmani M and Grant S: UCN-01 (7-hydroxystauorsporine) blocks PMA-induced maturation and reciprocally promotes apoptosis in human myelomonocytic leukemia cells (U937). Cell Cycle 1:273-281,2002.
13. Ghosh S, May MJ and Kopp EB: NF-κB and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol 16: 225-260, 1998.
14. Baldwin AS: Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB. J Clin Invest 107: 241-246, 2001.
15. Yamamoto Y and Gaynor RB: Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer. J Clin Invest 107: 135-142, 2001.
16. Rabson AB and Weissmann D: From microarray to bedside: targeting NF-κB for therapy of lymphomas. Clin Cancer Res 11: 2-6, 2005.
17. Cahir-McFarland ED, Carter K, Rosenwald A, Giltnane JM, Henrickson SE, Staudt LM and Kieff E: Role of NF-κB in cell survival and transcription of latent membrane protein 1- expressing or Epstein-Barr virus latency Ill-infected cells. J Virol 78: 4108-4119, 2004.
18. Kucharczak J, Simmons MJ, Fan Y and Gelinas C: To be, or not to be: NF-κB is the answer - role of Rel/NF-κB in the regulation of apoptosis. Oncogene 22: 8961-8982, 2003.
19. Hohmann HP, Remy R, Scheidereit C and van Loon AP: Maintenance of NF-kappaB activity is dependent on protein synthesis and the continuous presence of external stimuli. Mol Cell Biol 11:259-266. 1991.
20. Pennington KN, Taylor JA, Bren GD and Paya CV: IkappaB kinase-dependent chronic activation of NF-kappaB is necessary for p21(WAF1/Cip1) inhibition of differentiation-induced apoptosis of monocytes. Mol Cell Biol 21: 1930-1941, 2001.
21. Busuttil V, Bottero V, Frelin C, Imbert V, Ricci JE, Auberger P and Peyron JF: Blocking NF-kappaB activation in Jurkat leukemic T cells converts the survival agent and tumor promoter PMA into an apoptotic effector. Oncogene 21: 3213-3224, 2002.
22. Guzman ML, Neering SJ, Upchurch D, Grimes B, Howard DS, Rizzieri DA, Luger SM and Jordan CT: Nuclear factor-κB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood 98: 2301-2307, 2001.
23. Baumgartner B, Weber M, Quirling M, Fischer C, Page S, Adam M, von Schilling C, Waterhouse C, Schmid C, Neumeier D and Brand K: Increased IκB kinase activity is associated with activated NF-kappaB in acute myeloid blasts. Leukemia 16: 2062-2071,2002.
24. Homma Y, Henning-Chubb CB and Huberman E: Translocation of protein kinase C in human leukemia cells susceptible or resistant to differentiation induced by phorbol 12-myristate 13-acetate. Proc Natl Acad Sci USA 83: 7316-7319, 1986.
25. Yang KD, Mizobuchi T, Kharbanda SM, Datta R, Huberman E, Kufe DW and Stone RM: All-trans retinoic acid reverses phorbol ester resistance in a human myeloid leukemia cell line. Blood 83: 490-496, 1994.
26. Mori N, Yamada Y, Ikeda S, Yamasaki Y, Tsukasaki K, Tanaka Y, Tomonaga M, Yamamoto N and Fujii M: Bay 11- 7082 inhibits transcription factor NF-kappaB and induces apoptosis of HTLV-I-infected T-cell lines and primary adult T-cell leukemia cells. Blood 100: 1828-1834, 2002.
27. Pham LV, Tamayo AT, Yoshimura LC, Lo P and Ford RJ: Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis. J Immunol 171: 88-95, 2003.
28. Dai Y, Pei XY, Rahmani M, Conrad DH, Dent P and Grant S: Interruption of the NF-κB pathway by Bay 11-7082 promotes UCN-01-mediated mitochondrial dysfunction and apoptosis in human multiple myeloma cells. Blood 103: 2761-2770, 2004.
29. Pierce JW, Schoenleber R, Jesmok G, Best J, Moore SA, Collins T and Gerritsen ME: Novel inhibitors of cytokineinduced I-kappa-B-alpha phosphorylation and endothelial cell adhesion molecule expression show anti-inflammatory effects in vivo. J Biol Chem 272: 21096-21103, 1997.
30. Zheng X, Chang RL, Cui XX, Avila GE, Lee S, Lu YP, Lou YR, Shih WJ, Lin Y, Reuhl K, Newmark H, Rabson A and Conney AH: Inhibitory effect of 12-O-tetradecanoylphorbol- 13-acetate alone or in combination with all-trans-retinoic acid on the growth of LNCaP prostate tumors in immunodeficient mice. Cancer Res 64: 1811-1820, 2004.
31. Motyl T, Grzelkowska K, Zimowska W, Skierski J, Wareski P, Ploszaj T and Trzeciak L: Expression of bcl-2 and bax in TGFbeta 1-induced apoptosis of L1210 leukemic cells. Eur J Cell Biol 75: 367-374, 1998.
32. Suh J, Payvandi F, Edelstein LC, Amenta PS, Zong WX, Gelinas C and Rabson AB: Mechanisms of constitutive NF-κB activation in human prostate cancer cells. Prostate 52: 183-200, 2002.
33. Schreiber E, Matthias P, Muller MM and Schaffner W: Rapid detection of octamer binding proteins with 'mini-extracts', prepared from a small number of cells. Nucleic Acids Res 17: 6419, 1989.
34. Cui XX, Chang RL, Zheng X, Woodward D, Strair R and Conney AH: A sensitive bioassay for measuring blood levels of 12-O-tetradecanoylphorbol-13- acetate (TPA) in patients: preliminary pharmacokinetic studies. Oncol Res 13: 169-174, 2002.
35. Hass R, Gunji H, Datta R, Kharbanda S, Hartmann A, Weichselbaum R and Kufe D: Differentiation and retrodifferentiation of human myeloid leukemia cells is associated with reversible induction of cell cycle-regulatory genes. Cancer Res 52: 1445-1450, 1992.
36. Meinhardt G and Hass R: Differential expression of c-myc, max and mxi1 in human myeloid leukemia cells during retrodifferentiation and cell death. Leuk Res 19: 699-705, 1995.
37. Kang HS, Jung HM, Jundo Y, Huh TL and Kim YH: Expression of the human homologue of the small nucleolar RNA-binding protein NHP2 gene during monocytic differentiation of U937 cells. Biochim Biophys Acta 1575: 31-39, 2002.
38. Hass R: Retrodifferentiation and cell death. Crit Rev Oncog 5: 359-371, 1994.
39. Frelin C, Imbert V, Griessinger E, Peyron AC, Rochet N, Philip P, Dageville C, Sirvent A, Hummelsberger M, Berard E, Dreano M, Sirvent N and Peyron JF: Targeting NF-κB activation via pharmacologic inhibition of IKK2-induced apoptosis of human acute myeloid leukemia cells. Blood 105: 804-811, 2005.
40. Datta R, Hallahan DE, Kharbanda SM, Rubin E, Sherman ML, Huberman E, Weichselbaum RR and Kufe DW: Involvement of reactive oxygen intermediates in the induction of c-jun gene transcription by ionizing radiation. Biochemistry (Mosc) 31: 8300-8306, 1992.
41. Tonetti DA, Henning-Chubb C, Yamanishi DT and Huberman E: Protein kinase C-beta is required for macrophage differentiation of human HL-60 leukemia cells. J Biol Chem 269: 23230-23235, 1994.
42. Zheng X, Ryan A, Patel N, Klemons S, Hansson A, Shih WJ, Lin Y, Huberman E, Chang RL and Conney AH: Synergistic stimulatory effect of 12-O-tetradecanoylphorbol-13-acetate and capsaicin on macrophage differentiation in HL-60 and HL-525 human myeloid leukemia cells. Int J Oncol 26: 441-448, 2005.